Recursion Pharmaceuticals

Recursion Pharmaceuticals built its identity around a simple but radical premise: that biology can be treated as a data problem. Founded in 2013 and headquartered in Salt Lake City, Utah, the company combines high-throughput cellular imaging, machine learning, and automation to map the effects of compounds across millions of biological experiments per week, generating one of the largest proprietary datasets in drug discovery.

The company went public on Nasdaq in 2021, trading under the ticker RXRX, and has since expanded its platform infrastructure significantly. Its Recursion OS integrates wet-lab robotics with computational models, enabling the company to generate and interpret biological data at a scale not feasible through conventional methods. This positions Recursion less as a traditional drug developer and more as a technology-driven drug discovery platform, with partnerships and licensing arrangements alongside its own pipeline.

Recursion's therapeutic focus spans oncology, rare genetic diseases, and infectious disease, with programmes emerging directly from its machine-learning-guided discovery process rather than target-by-target hypothesis generation. The company has established significant collaborations with large pharmaceutical organisations, using its platform to explore indications and compound interactions that would be difficult to surface through legacy approaches.

With operations extending beyond Utah and a growing team of scientists, engineers, and data specialists, Recursion represents a distinct category within the life sciences: a company where computational infrastructure is as central to the enterprise as laboratory science. Its model has attracted attention from investors and partners seeking industrialised, reproducible approaches to early-stage drug discovery.

Further information is available at recursion.com.